2a) The same weekend that Will Herrington @willkidney, @The_MRC @Kidney_Research UK @Oxford_NDPH presented #EMPA_KIDNEY results at #ASN22 (see https://t.co/EsU0HK4xfe & https://t.co/JeMvoJQB7T), #David_Preiss presented more data at #AHA22 . . . pic.twitter.com/8D9t7we1KZ
— cardio-met (@cardiomet_CE) November 16, 2022
2c) #EMPA_KIDNEY represented the contributions of 241 participating sites from 8 countries 🌎🌍, and was funded and sponsored by Boehringer Ingelheim. Primary results already published at 🔓https://t.co/RYOmhIEo4b. pic.twitter.com/KDucpCRqks
— cardio-met (@cardiomet_CE) November 16, 2022
4) AHA Scientific Sessions #AHA22 was held in Chicago Nov 5-7 & was attended by #cardiovascular professionals from across the globe. Scientific abstracts can be accessed at 🔓 https://t.co/jaOj3p5O29. #SGLT2i are now clearly viewed as #CV drugs, not just drugs for #DM!
— cardio-met (@cardiomet_CE) November 16, 2022
6) @willkidney has (https://t.co/EsU0HKlAhe) highlighted pt groups underrepresented in prior trials of #SGLT2i in #CKD. Did you pay attention? #EMPA_KIDNEY gave us our first good look at:
— cardio-met (@cardiomet_CE) November 16, 2022
a. older pts w/CKD
b. younger pts w/CKD
c. pts without diabetes w/CKD
d. pts w/ eGFR 20-45
8) Here’s the primary composite outcome . . . pic.twitter.com/dp4Vl4KGvu
— cardio-met (@cardiomet_CE) November 16, 2022
10) Likewise, as per tweet 7, the presence or absence of #T2D did not impact the primary outcomes benefit of #SGLT2i therapy: pic.twitter.com/rQ65mju2rW
— cardio-met (@cardiomet_CE) November 16, 2022
12a) So now that we have the long-awaited #EMPA_KIDNEY results (remember, we knew there was enuf benefit to stop early way back in March 22), how can we view the TOTALITY of evidence supporting #SGLT2i therapy in patients at risk of #CKD progression? @NatalieStaplin shows us: pic.twitter.com/wx4MSS1ou6
— cardio-met (@cardiomet_CE) November 16, 2022
13) So let’s look at the aggregate population & CV outcomes. Again, we see no real impact on outcomes considering +DM or -DM, except for #CKD. Pts without diabetes, w/ CKD still have limited data from a CV perspective (though there is clear benefit on kidney disease progression): pic.twitter.com/tkFNYSAcii
— cardio-met (@cardiomet_CE) November 16, 2022
15) #Glomerular_disease is of course important in patients with #CKD who do not have #DKD; here’s a closer look. There remains a huge majority of data on the left of that line of unity, favoring #SGLT2i therapy. pic.twitter.com/j57pjwpaT1
— cardio-met (@cardiomet_CE) November 16, 2022
17) There has been concern in the past over #SGLT2i and risk of euglycemic #DKA & rates of lower limb #amputations. The meta-analysis data here speak for themselves: there is clearly ⬆️ risk of #DKA in patients with #diabetes, but rates in type 2 diabetes are incredibly low. pic.twitter.com/gnSARYaq0Y
— cardio-met (@cardiomet_CE) November 16, 2022
19a) #EMPA_KIDNEY + the large meta-analysis: what conclusion would be INCORRECT to draw about #SGLT2i therapy in pts with #CKD? (choices below, please mark the INCORRECT response)
— cardio-met (@cardiomet_CE) November 16, 2022
20) c is incorrect and therefore is the right answer. Did you get it? Let the authors remind you of their conclusions, also published in the Lancet 🔓 https://t.co/LhjIMWkxM3 pic.twitter.com/lsccqV3vYz
— cardio-met (@cardiomet_CE) November 16, 2022
22) And here's the conclusion from the #AHA22 presentation: pic.twitter.com/GwL1PRjS4y
— cardio-met (@cardiomet_CE) November 16, 2022
24) Now proceed to https://t.co/6B5mZclEbV & collect your 0.5hr CE/#CME. Follow us for more congress updates & expert-led #accredited #cardiometabolic education!
— cardio-met (@cardiomet_CE) November 16, 2022
Special 👏 to @willkidney, @RichardHaynes3, @NatalieStaplin, and #David_Preiss.